Several CGRP receptor antagonists and antibodies developed as migraine therapies have minimal effect on blood pressure in healthy individuals.1,2 Evidence that CGRP plays a role in cardiovascular protection arises from acute studies where CGRP has been administered in rodent models of hypertension,3,4 using spontaneously hypertensive rats5,6 and α-CGRP–specific knockout (KO) mice.7 The beneficial effects of the native CGRP peptide have also been observed when administered for up to 24 hours to patients with congestive heart failure with no evidence of tolerance.8,9. This evidence concerns the gene CALCA and congestive heart failure.